PCSK9 inhibitors: A new improvement for health

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder characterized by high cholesterol levels.
• Patients with HeFH have an increased risk of premature cardiovascular events, such as acute myocardial infarction.
• Effective lipid-lowering therapy is crucial for managing HeFH and preventing complications.

Observation:

• The patient presented with HeFH and a history of acute myocardial infarction.
• Oral lipid-lowering medications were insufficient to achieve therapeutic goals.
• LDL-apheresis was initiated as a fortnightly treatment for 8 years.

Findings:

• Despite long-term LDL-apheresis, the patient's lipid profile may still require optimization.
• The advent of PCSK9 inhibitors presents a novel therapeutic avenue for managing refractory hypercholesterolemia.
• This case highlights the evolving treatment landscape for complex lipid disorders.

Implications:

• PCSK9 inhibitors offer a potentially more convenient and effective alternative to LDL-apheresis for select patients.
• This case underscores the importance of personalized treatment strategies in managing familial hypercholesterolemia.
• Further research is warranted to evaluate the long-term efficacy and safety of PCSK9 inhibitors in HeFH patients previously treated with apheresis.